Building on clinical trial and laboratory research insights from the past decade, the ITN has focused and deliberate strategies to achieving tolerance in each disease area. The research supported by the ITN has unlocked new therapeutic approaches and discovered new biomarkers that promise to change the way physicians treat patients. Explore ITN clinical trials below by using a search term or by sorting the specific trial categories. If you have questions or want more information about ITN clinical trials, contact us.
Clinical Trials
Completed
Principal Investigator:
Patrick Holt, University of Western Australia, Perth, AUS
Peter Sly, Telethon Institute for Child Health Research, Perth, AUS
The purpose of this study is to determine whether early childhood exposure to common allergens (substances that can trigger allergies and asthma) can prevent the development of asthma in children at high risk for developing the disease.
Learn more: Study Summary
Clinicaltrials.gov
Principal Investigator:
Peter Creticos, Johns Hopkins University, Baltimore, MD
This study will evaluate the effectiveness of a six-week course of a DNA-based vaccine for seasonal allergic rhinitis, also known as hayfever.
Learn more: Study Summary
Principal Investigator:
Thomas B. Casale, Creighton University School of Medicine, Omaha, NE
A series of allergy shots may reduce symptoms of seasonal ragweed
allergies. This study will determine whether taking a drug called
omalizumab (also known as Xolair) before getting the allergy shots is
more effective than allergy shots alone or other treatments, such as
prescription antihistamines.
Learn more: Study Summary
Clinicaltrials.gov